{"nctId":"NCT00628758","briefTitle":"A Comparison of SymbicortÂ® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","startDateStruct":{"date":"2005-12"},"conditions":["Asthma"],"count":430,"armGroups":[{"label":"Symbicort","type":"EXPERIMENTAL","interventionNames":["Drug: Symbicort TBH - Turbuhaler"]},{"label":"Conventional BP","type":"EXPERIMENTAL","interventionNames":["Drug: beta-II-agonist, inhale steroid"]}],"interventions":[{"name":"Symbicort TBH - Turbuhaler","otherNames":[]},{"name":"beta-II-agonist, inhale steroid","otherNames":["Astmerol inh 25 mcg/dosage, 60-120 dosage","Astmerol maksihaler 50 mcg/dosage, 28-60 dosage","Serevent diskus 50 mcg/dosage, 60 dosage","Serevent inh 25 mcg/dosage, 60 dosage","Foradil inh kap 12 mcg/dosage, 60 caps","Foradil inh 12 mcg/dosage, 50-100 dosage","Foradil combi 200 mcg","Foradil combi 400 mcg","Oxis turbuhaler 4.5-9 mcg/dosage, 60 dosage","Ventofor 12mg/60 inh.caps","Seretide disc 100-250-500 mcg/dosage 60 dosage","Symbicort 160/4.5 mcg/60-120 dosage, 320/9mcg/60 dosage"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent form. If the patient cannot read and write, verbal consent from the patient is required.\n* Ability to read and write in Turkish\n* Female or male outpatients aged 18 years\n* Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition\n* Prescribed inhaled glucocorticosteroid (GCS) at a dose of 320mg/day and within the approved label for the relevant drug during the last 3 months prior to Visit 1\n* Either: daily maintenance treatment with both inhaled GCS and long-acting b2-agonist (LABA) or daily treatment with inhaled GCS alone (i.e. without LABA); and a history of suboptimal asthma control the month prior to enrollment as judged by the investigator; and use of 3 Peak Expiratory Flow inhalations ofas needed medication for symptom relief during the last 7 days before enrollment\n\nExclusion Criteria:\n\n* Previous treatment with Symbicort Single inhaler Therapy\n* Use of any b-blocking agent, including eye drops\n* Use of oral GCS as maintenance treatment\n* Known or suspected hypersensitivity to study therapy or excipients\n* A history of smoking 10 pack years\n* Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator\n* Any significant disease or disorder, which, in the opinion of the investigator, may put the patient at risk because of participating in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to First Severe Asthma Exacerbation","description":"Time to severe exacerbation among patients","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120.3","spread":"47.0"},{"groupId":"OG001","value":"103.7","spread":"32.7"}]}]}]},{"type":"SECONDARY","title":"Number of Severe Asthma Exacerbations","description":"Total number of severe asthma exacerbations per treatment group","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Standardised Asthma Quality of Life Questionnaire (AQLQ(S)) Score","description":"Quality-of-Life assessment; grouped in four domains;activity limitation, symptoms, emotional function and exposure to environmental stimuli, using with a scale from 1 to 7 where 1 represents the greatest possible impairment and 7 represents the least impairment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.98","spread":"1.12"},{"groupId":"OG001","value":"3.97","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"Mean Use of As-needed Medication Per Day During Treatment Period","description":"Mean use of as-needed medication per day during treatment period","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.91","spread":"7.6"},{"groupId":"OG001","value":"0.68","spread":"5.7"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":209},"commonTop":[]}}}